Search clinical trials for: MOA-728

Total 4333 results

Bausch Health Americas, Inc.

Withdrawn

Study Evaluating MOA-728 Administered in Healthy Men

Healthy
Bausch Health Americas, Inc.

Completed

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

Healthy

United States
Bausch Health Americas, Inc.

Completed

Bioequivalence Study in Healthy Volunteers

Healthy

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Postoperative Complications | Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain

Constipation
Bausch Health Americas, Inc.

Completed

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

Healthy

United States
Bausch Health Americas, Inc.

Withdrawn

Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy

Methadone-maintenance Subjects

United States
Bausch Health Americas, Inc.

Completed

Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone

Metahdone-maintenance Subjects

United States
Bausch Health Americas, Inc.

Completed

Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects

Constipation

United States
Bausch Health Americas, Inc.

Completed

Dose Ranging Study in Healthy Methadone Maintenance Subjects

Adult

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance

Methadone-maintenance Subjects

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

Recurrent Lung Squamous Cell Carcinoma | Stage IV Lung Squamous Cell Carcinoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia

United States
Bausch Health Americas, Inc.

Completed

Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus

Post Operative Bowel Dysfunction

Germany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Ileus

United States, South Africa, Canada, Hungary, Poland, Australia, Belgium, Germany, Italy, Korea, Republic of, Netherlands
National Cancer Institute (NCI)

Terminated

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

High Grade Sarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated... and other conditions

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Constipation

Korea, Republic of, Taiwan
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Withdrawn

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Opioid-Induced Constipation

Canada, United States, France, Spain
National Cancer Institute (NCI)

Terminated

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Glioblastoma | Gliosarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Recurrent Bladder Carcinoma | Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Metastatic Transitional Cell Carcinoma

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, United Kingdom, Brazil, Spain, Sweden
National Cancer Institute (NCI)

Recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Leptomeningeal Neoplasm | Recurrent Lung Non-Small Cell Carcinoma

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Sangamo Therapeutics

Completed

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

HIV Infection | HIV

United States
Bausch Health Americas, Inc.
Pfizer

Completed

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

Constipation

Canada, United States, Colombia, Korea, Republic of, Australia, Spain
Sangamo Therapeutics

Completed

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

HIV Infections | HIV Infection

United States
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Ariston Pharmaceuticals, Inc.

Unknown

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

Migraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura

Finland, Netherlands, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Polycythemia Vera | Essential Thrombocythemia

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Yellow Fever | Yellow Fever Immunisation

United States
Universitätsklinikum Hamburg-Eppendorf
Ludwig-Maximilians - University of Munich; Philipps University Marburg Medical... and other collaborators

Completed

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

Covid19

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory Neoplasm

United States
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

A Follow-up Evaluation Study of PRI-724-1101

Hepatitis C Virus-infected Cirrhosis

Japan
Blueprint Medicines Corporation

Completed

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

Healthy Volunteers

United States
Komagome Hospital
Japan Agency for Medical Research and Development; Prism Pharma Co., Ltd.

Completed

An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis

Hepatitis C Virus-infected Cirrhosis

Japan
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
Rhythm Pharmaceuticals, Inc.

Recruiting

A Study of RM-718 in Healthy Subjects and in Patients With HO

Hypothalamic Obesity

United States
Chong Kun Dang Pharmaceutical

Completed

Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects

Hypertension

Korea, Republic of
Durect
CTI Clinical Trial and Consulting Services

Completed

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis (AH)

Alcoholic Hepatitis

United States
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia
Akinion Pharmaceuticals AB

Terminated

Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia

Acute Myeloid Leukemia

Sweden, Poland, Czech Republic, United Kingdom
Dr. Tapas K. Das Gupta

Completed

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

Refractory Solid Tumors

United States
European Organisation for Research and Treatment...

Withdrawn

CHS 828 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Norway, Switzerland, Netherlands, Belgium, Austria, United Kingdom, Denmark, Germany
Takeda

Terminated

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies

Search clinical trials for: MOA-728

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations